Save Product
Product Details
- ItemsSize 2mgSize 10mg (5mg × 2)Particle size2 μm2 μmPhysical appearancePowder mixturePowder mixtureBinding Capacity>2265 pmol (35μg) Anti Human CD3/mg beads>2265 pmol (35μg) Anti Human CD3/mg beadsFormulationPBS, pH7.4, with 10% TrehalosePBS, pH7.4, with 10% TrehaloseReconstitution2 mL sterile deionized water (1 mg beads/mL)5 mL sterile deionized water (1 mg beads/mL)
Product Description
The Human CD3E-coupled Magnetic Beads is produced by coupling biotinylated CD3E protein to streptavidin-conjugated magnetic beads. Because Streptavidin (SA) has an extraordinarily high affinity for biotin with a dissociation constant (Kd) on the order of 10-14 mol/L, the biotinylated protein can bind to the SA beads irreversibly. The pre-coupled beads are ready to use for capturing anti-CD3E antibody from your sample with high specificity.
Application
This product is intended for immunocapture, biopanning. This is a non-sterile product.
* The Isotype control (Cat. No. SMB-B01) is sold separately.
Reconstitution
See Certificate of Analysis (CoA) for detailed instruction.
Storage
Upon receipt, please store the beads at -20°C for 1 year in lyophilized state.
Please avoid more than 3 freeze-thaw cycles once reconstitution, immediate use after reconstitution is highly recommended.
Assay Principles
Antibody Purification:
1. Resuspend the lyophilized beads by adding the buffer of choice.
2. Add analyte to the suspension, mix and incubate to enable specific binding of the beads and the target protein.
3. Magnetize beads, remove supernatant, and wash unbound protein fractions to capture target protein-bound beads.
4. Wash, magnetize the beads and collect purified target protein for use in downstream applications.The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Typical Data
Immobilized 4.1 μg CD3E/1mg beads can bind the Anti Human CD3 Antibody (Cat. No. 551916) with an EC50 of 0.9022 μg/mL.
Protocol
Accelerated stability test. After placing the lyophilized beads at 37°C for 7 days, binding activity between the Human CD3E-coupled Magnetic Beads (Cat.No. MBS-K026) and anti-CD3 antibody showed little deviation from the unaccelerated sample (%RSD<10%). Data were measured on day 0, 3, 7 respectively.
Protocol
Freeze-thaw stability test. After different freeze-thaw cycles, binding activity between the Human CD3E-coupled Magnetic Beads (Cat.No. MBS-K026) and anti-CD3 antibody showed little deviation from the unfreeze-thaw sample (%RSD<10%). Three freeze-thaw cycles were performed.
Protocol
Customer Reviews Writing Reviews
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Recent Advances
Drug Development Progress- English Name：
T-cell surface glycoprotein CD3 epsilon chain
- Category：
- Approved Drugs：
4 Details
- Drugs in Clinical Trials：
7 Details
- Highest Development Stage：
Approved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
